ForPatients

by Roche

Huntington's Disease (HD2)

A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease

Trial Status Trial Runs In Trial Identifier

Completed 2 Countries NCT04000594 GEN-PEAK
BP40410

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

Study BP40410 is an open-label, adaptive multiple-dose clinical study designed to characterize the PK of RO7234292 (RG6042) in plasma and CSF as well as the acute time course and recovery profile of CSF mHTT lowering in response to RO7234292 (RG6042) treatment after intrathecal (IT) administration of RO7234292 (RG6042) to patients with manifest Hungtington's disease (HD).

Hoffmann-La Roche Sponsor	Phase 1 Phase		
NCT04000594 GEN-PEAK BP4 Trial Identifiers	0410		
Eligibility Criteria:			
Gender All	Age >=25 Years & <= 65 Years	Healthy Volunteers	